The European Medicines Agency's Management Board has nominated Guido Rasi on June 8,2011 as new Executive Director of the Agency. The Executive Director-designate has been invited to a hearing in front of the European Parliament Committee on Environment, Public Health and Food Safety on July 13, 2011. The Board will officially appoint the new Executive Director following his hearing and a positive response from the European Parliament.
Mr. Rasi has been Director-General of the Italian Medicines Agency since 2008, and member of the European Medicines Agency's Management Board since 2010.
Mr. Rasi holds a degree in medicine and surgery, with specialization in internal medicine, allergology, and clinical immunology from the University of Rome. From 1978 to 1990, Mr. Rasi worked as physician in hospital, research, and private practice. He worked from 1990 to 2008 in research at the Institute for Experimental Medicine of the National Research Council in Rome, directing the molecular medicine section from 2002 to 2005 and the Tor Vegata section from 2005 to 2008. He was made full professor of microbiology at the University of Rome (Tor Vegata) in 2008.
Andreas Pott will continue his role as Acting Executive Director until Guido Rasi takes office.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.